In June 2013, the European Commission published a report on the first five years of the Paediatric Regulation that came into force in the European Union (EU) on 26 January 2007. The regulation aimed to improve the health of children in Europe by facilitating the development and availability of medicines for children aged 0 to 17 years, and ensure that medicines for use in children are of high quality, ethically researched and authorised appropriately. But the inclusion of children in clinical research brings unique complexities.  Elizabeth Moench of MediciGlobal Ltd. discusses why paediatric clinical trials involve a distinctive set of challenges that can result in increased costs for patient retention, as well as additional time required to develop customized and meaningful retention programs.
http://jforcs.com/jcs/wp-content/uploads/2013/10/Pediatric…pdf